GlassScriptPhysician profile
Mauricio Garcia
NPI 1942284427
$7,852.50
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,145 · 2020: $930 · 2021: $3,105 · 2022: $928 · 2023: $580 · 2024: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $745.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,222.00 | 2019-2024 | Proclaim, Eterna, Octrode |
| Ge Healthcare | $1,394.13 | 2021 | |
| Choice Spine, LLC | $908.81 | 2019-2021 | |
| Spinesmith Holdings, LLC | $510.77 | 2019 | |
| Nevro Corp. | $368.14 | 2020-2022 | |
| Spinal Elements, INC. | $350.86 | 2019 | |
| Vertiflex, INC. | $297.03 | 2019 | |
| Precision Spine, INC. | $288.00 | 2021 | |
| Abbvie INC. | $278.46 | 2021-2023 | |
| Baudax Bio INC. | $207.47 | 2020-2021 | |
| Sanara Medtech INC. | $150.84 | 2022 | |
| Ulrich Medical USA, INC. | $124.62 | 2019 | |
| Amgen INC. | $124.04 | 2021 | |
| Curiteva, INC. | $100.86 | 2019 | |
| Collegium Pharmaceutical, INC. | $89.39 | 2019-2024 | Belbuca |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $76.12 | 2023 | Exalt Model D |
| Biocomposites INC | $68.58 | 2019 | |
| Stryker Corporation | $50.59 | 2024 | Scopis Ent |
| Medtronic, INC. | $46.72 | 2021-2022 | |
| Pfizer INC. | $38.28 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $24.29 | 2024 | Orgovyx |
| Integra Lifesciences Corporation | $22.64 | 2023 | Tenoglide |
| Pacira Pharmaceuticals Incorporated | $20.40 | 2023 | Iovera, Zilretta |
| Forte Bio-Pharma LLC | $19.47 | 2024 | Prolate, Nalocet |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.94 | 2019 | |
| Merck Sharp & Dohme LLC | $15.41 | 2022 | |
| Grifols USA, LLC | $14.61 | 2022 | |
| Spine Wave, INC. | $13.12 | 2019 | |
| Endogastric Solutions, INC | $10.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mauricio Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.